What Biohm Technologies does

Biohm Technologies is a Cleveland-based microbiome science company that develops clinically validated probiotic, postbiotic, and gut-testing products for dietary supplement brands and health-and-wellness companies. Founded in 2016 by Afif Ghannoum and Dr. Mahmoud Ghannoum — the latter credited with coining the term 'mycobiome' — the company was originally known as Biohm Health, Inc. and sold directly to consumers; in September 2024 it rebranded to Biohm Technologies and refocused on a B2B model, appointing Sam Schatz as CEO. The company's portfolio centers on two proprietary ingredients, Mycohsa (a bacterial-fungal probiotic blend with three completed human clinical trials) and Phorum (a heat-treated postbiotic launched in October 2025), a white-labelable gut microbiome test kit using 16S and ITS sequencing, and the Symbiont discovery platform, which combines proprietary bacterial and fungal datasets, AI/ML developed in partnership with Virginia Tech, and intelligent search across scientific literature to design targeted formulations such as ViviFem (co-developed with ADM for women's health ages 40-65). Biohm monetizes through ingredient supply agreements with supplement manufacturers, white-label test kit partnerships, and co-development arrangements, with the most prominent enterprise relationships being ADM and the Canadian market enabled by Health Canada NPN approval. The company operates an 11-50 employee team from Cleveland headquarters, a research laboratory at Portal Innovations' Science Square campus in Atlanta, and is backed by VTC Ventures, Praesidium, and Sparkfood by Sonae.

Name

Biohm Technologies

Legal name

Biohm Health, Inc.

Website

https://biohmtechnologies.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Short description

Biohm Technologies is a Cleveland-based microbiome company that develops clinically validated probiotic (Mycohsa) and postbiotic (Phorum) ingredients, white-label gut test kits, and the AI-powered Symbiont discovery platform for dietary supplement brands and health-and-wellness companies, with a recent ADM partnership for women's-health formulations.

Ownership category

akta.pro rank

Product category

Microbiome Ingredients and Testing

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), In-Vitro Diagnostic Substance Manufacturing (325413), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Food And Kindred Products (2000), In Vitro & In Vivo Diagnostic Substances (2835), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Microbiome Manufacturing, Formulation & Delivery Technologies (encapsulation, spores, oral delivery) (HLAAAFAJ)

akta.pro secondary industries

Microbiome Diagnostics & Biomarker Platforms (gut/skin/oral/vaginal) (HLAAAFAH), Microbiome Analytics, Sequencing & Bioinformatics Platforms (HLAAAFAI)

Keywords

• Microbiome ingredients
• Probiotic blends
• Postbiotic ingredients
• Gut microbiome testing
• Nutraceutical biotechnology

Headquarters

HQ city

Cleveland

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales

Revenue model

1. B2B Ingredient Sales: Biohm Technologies sells its probiotic blend Mycohsa and postbiotic Phorum as ingredients to dietary supplement brands for use in their products. Ingredients are sold in bulk for formulation into capsules, powders, and chewable tablets. Revenue is generated through ingredient supply agreements with brand partners.
2. Private Label Testing Services: Biohm offers white-label gut microbiome test kits to health and wellness brands, providing comprehensive analysis of bacterial and fungal species with branded online portals and personalized reports. Brands can offer these to their customers for engagement and loyalty purposes.
3. Formulation Development Partnerships: Co-development agreements with ingredient companies and brands to create targeted microbiome formulations using Biohm's Symbiont platform and dataset, such as the ViviFem partnership with ADM.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

Biohm Technologies is a B2B ingredient and technology supplier that develops, manufactures, and licenses proprietary microbiome ingredients (Mycohsa probiotic blend and Phorum postbiotic) to dietary supplement brands for formulation into finished products. The company also provides white-label gut microbiome test kits to brand partners and operates the Symbiont AI-powered discovery platform for microbiome ingredient development. Its differentiator is the systematic combination of bacterial and fungal (mycobiome) community data, supported by 3 human clinical trials and 12+ pre-clinical studies.

Product overview

Biohm Technologies offers a portfolio of microbiome-focused products centered around two core ingredients (Mycohsa™ probiotic and Phorum™ postbiotic), supported by a proprietary gut microbiome test kit platform and the Symbiont® AI-powered discovery platform. Mycohsa and Phorum are B2B ingredient offerings sold to dietary supplement manufacturers, while the gut test kits serve as both a consumer product and white-label solution for brand partners. The Symbiont platform underpins product development by leveraging one of the world's largest microbiome datasets combining bacterial and fungal genetic sequencing. Recent additions include the Longevity Gut Report AI feature and ViviFem (a women's health formulation developed with ADM).

Differentiator

Problem solved

Functional benefit

Brands

• Mycohsa™: Flagship probiotic blend designed to address both bacterial and fungal communities in the microbiome, clinically proven to break down digestive biofilms. Supported by 3 human clinical trials and 12+ pre-clinical studies.
• Phorum™
• Symbiont®
• ViviFem™

Products and services

• Mycohsa Flagship probiotic blend combining beneficial bacteria (Lactobacillus acidophilus 16axg, Lacticaseibacillus rhamnosus 18fx, Bifidobacterium breve 19bx) with beneficial fungi (Saccharomyces boulardii 16mxg) and a digestive enzyme (amylase). Clinically proven to break down digestive biofilms and support optimal levels of both bacteria and yeasts. Sold as a B2B ingredient to dietary supplement brands for formulation into capsules, powders, and chewable tablets.
• Phorum Next-generation postbiotic ingredient developed from heat-treated bacterial and fungal strains (Lactobacillus acidophilus 16axg, Lacticaseibacillus rhamnosus 18fx, Saccharomyces boulardii), delivering stable bioactive compounds including cell wall fragments, enzymes, peptides, and organic acids without requiring live organisms. Designed to support healthy immune function. Sold as a B2B ingredient to dietary supplement brands.
• Gut Microbiome Test Kits At-home gut microbiome test kits analyzing both fungal and bacterial species in the gut using 16S and ITS sequencing methods. Provides a proprietary Gut Score across four criteria (Microbiome Diversity, Phyla Balance, Beneficial Species, Pathogenic Species), personalized diet and lifestyle recommendations, and actionable insights. Available directly to consumers and as a private label solution for brand partners for consumer engagement and loyalty.
• Symbiont Discovery Platform Biohm's systematic approach to ingredient discovery, selection, and formulation, leveraging one of the world's largest microbiome datasets. Combines bacterial and fungal genetic sequencing with over 50 metadata points and AI/machine learning algorithms (via Virginia Tech partnership) to identify biomarkers and optimal ingredients for target demographics. Validated and published in Gastroenterology. Used by Biohm and partners such as ADM to co-develop targeted microbiome formulations.
• ViviFem Data-driven, targeted microbiome formulation for women aged 40-65, developed in partnership with ADM. Combines pre-, pro-, and postbiotics including Mycohsa probiotic blend, PreforPro prebiotic, and ES1 postbiotic, supported by seven published human clinical trials and dozens of pre-clinical studies. Designed to address microbiome misalignments in aging women.

Quantifiable outcome

• Clinically proven to break down digestive biofilms and support optimal levels of both bacteria and yeasts
• +3 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature5 records

Partnerships

Three partnerships are on record, tiered major and core.

• Portal InnovationsmajorStrategic or Co-development Partner · 5 November 2025Biohm opened its new 33,000-square-foot research laboratory at Portal Innovations' Science Square campus in Atlanta. The facility provides access to shared infrastructure, $2M+ in equipment, and BSL-2 capability, enabling Biohm to focus capital on people and research rather than infrastructure buildout.
• ADM (Archer Daniels Midland)coreStrategic or Co-development Partner · 15 October 2024Joint development of ViviFem, a targeted microbiome formulation for women's health ages 40-65. ADM employed Biohm's Symbiont platform to create a combination of pre-, pro-, and postbiotics addressing microbiome misalignments in aging women. The formulation includes Mycohsa, PreforPro, and ES1. Seven published human clinical trials and dozens of pre-clinical studies support the ingredients.
• Virginia TechcoreTechnology or Integration · 7 March 2024Strategic partnership to enhance Symbiont platform through AI/ML technology development. Virginia Tech researchers developing predictors using machine learning algorithms to link microbial populations to phenotypes for biomarker identification. Dan Sui, Senior Vice President for Research and Innovation at Virginia Tech, emphasized importance of industry-university collaboration for innovation. Brian Mixer noted VTC Ventures' thesis of leveraging Virginia Tech's research capabilities.

Scale indicators13 records

Recent moves8 records

Expansion highlights6 records

Broad incumbents

• Novozymes (Novonesis): Novozymes (merged into Novonesis) is a global enzyme and microbiome technology platform serving food, health, and industrial markets. Comparable in microbiome-adjacent science and ingredient supply scale, though broader in scope.
• BioGaia: BioGaia is a long-established Swedish probiotic ingredient company supplying L. reuteri strains to supplement and infant formula brands globally. Comparable to Biohm as a science-backed B2B probiotic ingredient supplier, but much larger and bacterial-only focused.
• Chr. Hansen (Novonesis): Chr. Hansen (now part of Novonesis) is one of the world's largest producers of probiotic bacterial cultures for supplement, dairy, and infant nutrition applications. Comparable as a B2B microbiome ingredient incumbent but operates at industrial scale and lacks a fungal/mycobiome thesis.

Emerging players

• Deerland Probiotics & Enzymes: Deerland is a U.S. probiotic and enzyme ingredient supplier now owned by ADM and a Biohm partner. Comparable in the B2B probiotic/prebiotic ingredient space, though its portfolio is bacterial-focused versus Biohm's bacterial-fungal thesis.

Direct peers

• Viome: Viome sells at-home gut microbiome test kits combined with personalized nutrition/supplement recommendations. Comparable to Biohm on the consumer-facing test + insights side, though Viome is consumer-direct rather than B2B.
• Pendulum Therapeutics: Pendulum develops targeted probiotic formulations backed by clinical trials for specific health conditions (metabolic health). Highly comparable to Biohm's Mycohsa approach of clinically validated, condition-specific microbiome interventions.
• Seed Health: Seed Health develops science-backed probiotic and prebiotic formulations with proprietary microbiome science, including bacterial-fungal considerations. Comparable to Biohm as a science-led microbiome ingredient company with consumer and partner offerings.
• Zoe: Zoe combines gut microbiome testing with personalized nutrition scoring and recommendations. Directly comparable to Biohm's gut test kit + personalized insights offering, though Zoe is consumer-direct and primarily UK/US focused.
• Sun Genomics: Sun Genomics offers personalized probiotic formulations based on individual gut microbiome testing results. Comparable to Biohm in combining microbiome sequencing with custom-formulated biotic products.

Others

• ADM: ADM is Biohm's largest enterprise partner and acquired Deerland Probiotics & Enzymes. Comparable as a customer/distributor for microbiome ingredients and as a potential acquirer of microbiome IP, though its core business is broad agricultural commodity processing.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/biohm-technologies
• Xx.com/biohmhealth

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds6 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biohm Technologies